We would like to share with you some examples of studies that our clients have often asked us about using the IPF model.

CohBar, Inc. (NASDAQ: CWBR), a clinical-stage biotechnology company developing mitochondria-based therapeutics also announced interesting data with our IPF model at the American Thoracic Society’s Virtual 2020 Conference.

The ePoster presents data on CohBar’s MBT2 (CB5138-1), which is an analog of a mitochondrially encoded peptide, CB5138.

CB5138-1 decreased lung fibrosis and inflammation in both the prophylactic mouse and the therapeutic mouse model.

In addition, two new analogs of CB5138 (CB5138-2 and CB5138-3) significantly reduced lung fibrosis assessed by the Ashcroft Score, reduced inflammation, and decreased fibrosis-related changes in lung weight, collagen deposition in lung tissue, and collagen secretion into lung fluid.

Epstein-Shochet G et al, 2020 used our IPF model for the optimization of nintedanib's pharmacokinetic/pharmacodynamic project and get a very promising data.

In addition to the above, we have data reported by our clients and have evaluated over 90 compounds to date.

If you are interested in our IPF model and its use, please do not hesitate to contact us.